**Amendments to the Specification:**

Please replace the 1st paragraph of page 1 with the following rewritten paragraphs:

Reference to Related Applications

This is a divisional of ~~copending applications Serial number~~ U.S.S.N. 08/400,796 filed on March 7, 1995, now U.S. Pat. No. 5,874,531.

**Amendments to the Specification:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-2. **(Cancelled)**

3. **(Currently amended)** A pharmaceutical preparation for ~~tolerizing~~ tolerization, comprising a pharmaceutically acceptable carrier and

an amount of an isolated human polypeptide effective for tolerizing an individual to an autoantigen, said human polypeptide consisting of a sequence motif for an HLA-DR protein containing the core MHC binding residues, wherein said HLA-DR protein is selected from the group consisting of HLA-DR2 and HLA-DR4 ~~consisting essentially of an amino acid sequence corresponding to the core MHC binding residues of a sequence motif for an HLA-DR protein~~;

wherein said sequence motif for said HLA-DR protein is based upon the structure of the HLA-DR peptide binding site;

wherein said HLA-DR protein is associated with a human autoimmune disease selected from Pemphigus Vulgaris (PV) and Multiple Sclerosis (MS);

wherein said polypeptide binds to said HLA-DR protein;

wherein said polypeptide bound to said HLA-DR protein activates autoreactive T cells from a subject having said autoimmune disease; and

wherein said ~~protein~~ human polypeptide is a ~~non-collagen and~~ non-myelin basic protein polypeptide.

4. **(Original)** The pharmaceutical preparation of claim 3 wherein said HLA-DR protein is an HLA-DR4 protein and said autoimmune disease is pemphigus vulgaris.

5. **(Original)** The pharmaceutical preparation of claim 4 wherein said motif is PV motif #1.

6. **(Currently amended)** The pharmaceutical preparation of claim 4, wherein said ~~amino acid sequence~~ polypeptide consists ~~essentially~~ of an amino acid sequence selected from

~~the group consisting of~~ SEQ ID NO~~.~~: 1, SEQ ID NO~~.~~: 2, SEQ ID NO~~.~~: 3, SEQ ID NO~~.~~: 4, SEQ ID NO~~.~~: 5, SEQ ID NO~~.~~: 6, ~~and~~ or SEQ ID NO~~.~~: 7.

7-10. **(Cancelled)**

11. **(Original)** A method of tolerizing an individual to an autoantigen of pemphigus vulgaris comprising administering an effective amount of the pharmaceutical preparation of any one of claims 4-6 to a subject in need of such treatment.

12-29. **(Cancelled)**

30. **(New)** A pharmaceutical preparation for tolerization, comprising a pharmaceutically acceptable carrier and

an amount of an isolated human pathogen polypeptide effective for tolerizing an individual to said human pathogen polypeptide, said human pathogen polypeptide consisting of a sequence motif for an HLA-DR protein containing the core MHC binding residues, wherein said HLA-DR protein is selected from the group consisting of HLA-DR2 and HLA-DR4;

wherein said sequence motif for said HLA-DR protein is based upon the structure of the HLA-DR peptide binding site;

wherein said HLA-DR protein is associated with a human autoimmune disease selected from Pemphigus Vulgaris (PV) and Multiple Sclerosis (MS);

wherein said human pathogen polypeptide binds to said HLA-DR protein;

wherein said human pathogen polypeptide bound to said HLA-DR protein activates autoreactive T cells from said individual having said autoimmune disease.

31. **(New)** The pharmaceutical preparation of claim 30 wherein said HLA-DR protein is an HLA-DR4 protein and said autoimmune disease is pemphigus vulgaris.